7 Analysts Have This to Say About Verrica Pharmaceuticals
Portfolio Pulse from Benzinga Insights
In the last quarter, Verrica Pharmaceuticals (NASDAQ:VRCA) received 6 bullish and 1 somewhat bullish ratings from analysts. The company's average 12-month price target has increased by 2.64% from $11.00 to $11.29.
October 12, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Verrica Pharmaceuticals received positive ratings from analysts, which could boost investor confidence and potentially increase the stock price.
Analyst ratings often influence investor sentiment. In this case, Verrica Pharmaceuticals received mostly bullish ratings, which indicates a positive outlook for the company. This could lead to increased investor confidence and a potential rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100